Keyphrases
Adjuvant Chemotherapy
7%
Anal Carcinoma
6%
Chemoradiation
10%
Chemotherapy
18%
Clinical Complete Response
13%
Clinical Practice Guidelines
6%
Colon Cancer
22%
Colorectal Cancer
92%
Colorectal Surgery
17%
Complete Response
8%
Confidence Interval
5%
Consolidation Chemotherapy
9%
Crohn's Disease
12%
Disease-free Survival
16%
FOLFOX Chemotherapy
6%
Ileal Crohn's Disease
6%
Ileal Pouch-anal Anastomosis
6%
Ileum
6%
Inflammatory Bowel Disease
9%
Locally Advanced Rectal Cancer
10%
Metastatic Colorectal Cancer (mCRC)
9%
Metastatic Disease
11%
NCCN Guidelines
20%
Neoadjuvant
9%
Neoadjuvant Chemoradiotherapy (nCRT)
10%
Neoadjuvant Therapy
7%
Nonoperative Management
18%
Oncology
9%
Organ Preservation
12%
Overall Survival
11%
Paneth Cells
5%
Pathological Complete Response
5%
Pathological Stage
5%
Phase II Trial
6%
Preoperative Chemotherapy
6%
Proctectomy
10%
Radiotherapy
5%
Rectal Adenocarcinoma
16%
Rectum
6%
Recurrent Disease
6%
Resection
9%
Short-course Radiation Therapy
20%
Surgeons
7%
Surgical Management
8%
Survivorship
6%
Systemic Therapy
6%
Total Neoadjuvant Therapy
23%
Transanal Total Mesorectal Excision (taTME)
9%
Tumor
7%
Watch-and-wait
11%
Medicine and Dentistry
Adjuvant Chemotherapy
6%
Anus Carcinoma
6%
Cancer Surgery
5%
Cancer Therapy
9%
Chemoradiotherapy
24%
Colectomy
5%
Colon
9%
Colon Carcinoma
19%
Colorectal Surgery
8%
Consolidation Chemotherapy
10%
Crohn's Disease
11%
Disease Free Survival
18%
Diseases
22%
Fistula
5%
FOLFOX
9%
Ileum
5%
Inflammatory Bowel Disease
8%
Local Excision
5%
Magnetic Resonance Imaging
9%
Malignant Neoplasm
11%
Metastatic Carcinoma
11%
Metastatic Colorectal Cancer
5%
Minoxidil
9%
Neoadjuvant Therapy
26%
Neoplasm
17%
Oncology
7%
Overall Survival
14%
Pelvis
7%
Peroperative Complication
5%
Photoacoustic Microscopy
5%
Radiation Therapy
25%
Rectum Cancer
100%
Rectum Carcinoma
15%
Rectum Resection
13%
Recurrent Disease
12%
Retrospective Study
5%
Surgeon
9%
Surgical Anastomosis
7%
Surgical Margin
6%
Total Mesorectal Excision
9%